openPR Logo
Press release

Hyperuricemia - Pipeline Review, H1 2017

06-07-2017 08:02 AM CET | Health & Medicine

Press release from: ReportsWorldwide

ReportsWorldwide has announced the addition of a new report title Hyperuricemia - Pipeline Review, H1 2017 to its growing collection of premium market research reports.

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia - Pipeline Review, H1 2017, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.

High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.

To Enquire about this Report please visit @
https://www.reportsworldwide.com/report/hyperuricemia-pipeline-review-h1-2017

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)

To view a detailed description and Table of Contents please visit:
https://www.reportsworldwide.com/report/hyperuricemia-pipeline-review-h1-2017

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

About ReportsWorldwide.com
ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hyperuricemia - Pipeline Review, H1 2017 here

News-ID: 566760 • Views:

More Releases from ReportsWorldwide

World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence
New report explores the Gene Editing Market : Ushering The Next Breakthrough in Regenerative Medicine
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports. Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors. Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that
Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports. This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers: • CommScope/Airvana • Comba Telecom • Ericsson • Huawei Technologies • Nokia • SpiderCloud • ZTE Corporation This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021. To view a detailed description and Table of

More Releases for Hyperuricemia

Hyperuricemia Drugs Market Size, Share and Growth Report, 2034
" The hyperuricemia drug market is projected to reach a valuation of approximately $7.5 billion in 2024, driven by the rising prevalence of gout and escalating healthcare expenditures. The anticipated market growth for the period from 2025 to 2034 is expected to propel the market value to around $12 billion, reflecting an impressive Compound Annual Growth Rate (CAGR) of 5.4%. " Exactitude Consultancy., Ltd. released a research report titled "Hyperuricemia Drugs
What's Driving the Hyperuricemia Drugs Market 2025-2034: Rising Incidence Of Hyp …
What Are the Projections for the Size and Growth Rate of the Hyperuricemia Drugs Market? The market size of drugs for hyperuricemia has seen robust growth in the past few years. The market is expected to expand from $4.75 billion in 2024 to $5.16 billion in 2025, displaying a compound annual growth rate (CAGR) of 8.5%. The historical growth can be credited to factors such as the escalating cases of gout,
Hyperuricemia Market Statistical Forecast, Trade Analysis 2024 - 2031
DataM Intelligence has published a new research report on "Hyperuricemia Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/hyperuricemia-market The
Hyperuricemia Drugs Market: Insights and Forecast | 2024-2030
Hyperuricemia Drugs Market Overview: Maximize Market Research a business Analytics company has released a report on the "Hyperuricemia Drugs Market". As per the "Hyperuricemia Drugs report," the total market size value from 2023 and estimated value for 2030 with a CAGR forecasted from 2024 to 2030. Projected Growth in Revenue: The Hyperuricemia Drugs Market size was valued at USD 5.08 Billion in 2023 and the total Hyperuricemia Drugs Market revenue is expected to
Hyperuricemia Market Analysis and Precise Outlook 2020-2030
Hyperuricemia Market Insights, Epidemiology, and Market Forecast-2030: The Hyperuricemia market report provides current treatment practices, emerging drugs, Hyperuricemia market share of the individual therapies, current and forecasted Hyperuricemia market Size from 2017 to 2030 segmented by seven major markets. The report delivers an in-depth understanding of the Hyperuricemia, historical and forecasted epidemiology as well as the Hyperuricemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom)
Hyperuricemia-Pipeline Review H2 2018
Hyperuricemia-Pipeline Review, H2 2018 Summary Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia-Pipeline Review, H2 2018, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape. High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain